Sanofi wraps up €3,9 billion acquisition of Ablynx
Sanofi and Ablynx have completed the acquisition, as Sanofi has acquired all outstanding shares, warrants and convertible bonds of Ablynx.
Pharmaceuticals, Biotechnology and Life Sciences
Sanofi and Ablynx have completed the acquisition, as Sanofi has acquired all outstanding shares, warrants and convertible bonds of Ablynx.
Novartis’s eye care division Alcon unveils new data showing significantly improved near and intermediate distance vision with the AcrySof IQ…
Idorsia today is initiating a Phase 3 study React to test clazosentan for the prevention of clinical deterioration due to…
Recipharm and Sanofi announced today that they have signed an agreement to transfer the Holmes Chapel site from global healthcare…
TiGenix NV’s Chief Executive Officer, Eduardo Bravo will depart the board of directors and his role as CEO of TiGenix…
4D pharma has been cleared by the Medicines and Healthcare Products Regulatory Agency (MHRA) and the Health Products Regulatory Authority…
Santhera Pharmaceuticals said on Tuesday that the Korean Ministry of Food and Drug Safety (MFDS) has accepted its new drug…
The US Food and Drug Administration approved Merck’s Keytruda (pembrolizumab) for patients with recurrent or metastatic cervical cancer with disease…
Alvogen and Pfenex have signed a deal which grants Alvogen exclusive rights to commercialize Pfenex’s lead drug candidate, PF708, a…
The US Food & Drug Administration (FDA) has granted Fast Track designation to Nordic Nanovector’s Betalutin (177Lu-lilotomab satetraxetan) for the treatment of…